drugset / Trial / NCT07155226
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.
Timeline
- Start
- 2026-01-09
- Primary completion
- 2029-02-15
- Completion
- 2029-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD3632 | Unknown | — | Oral |
| Background | Posaconazole | Small molecule | — | Oral |